Company news
Oculis Holding AG news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Oculis Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema
December 17, 2023
Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Disease
December 6, 2023
Oculis Reports Q3 2023 Financial Results and Provides Company Update
November 14, 2023
Oculis to Present at Upcoming November Investor Conferences
November 7, 2023
Oculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular Edema
October 31, 2023
Positive Phase 3 Stage 1 DIAMOND Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress
October 9, 2023
Oculis to Present a Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edema
October 4, 2023
Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase
September 10, 2023
Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update
August 28, 2023
OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery
August 7, 2023
First Patient Enrolled in LEOPARD, an Investigator-Initiated Trial, with OCS-01 Eye Drops for the Treatment of Cystoid Macular Edema
August 1, 2023
Oculis Announces to Present at Upcoming August Investor Conferences
July 25, 2023
Oculis to Present at OIS Retina Innovation Summit
July 18, 2023
Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023
June 25, 2023
Oculis Announces Partial Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares
June 12, 2023
Oculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and Economics
June 11, 2023
Oculis to Participate in Jefferies Healthcare Conference
May 31, 2023
Oculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares
May 30, 2023
Oculis Announces Launch of Proposed Public Offering of Ordinary Shares
May 29, 2023
Oculis to Participate and Present at Upcoming EuDES Meeting
May 23, 2023
Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops
May 21, 2023
Oculis Co-founders Selected as Finalists in European Inventor Award 2023
May 10, 2023
Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs
April 25, 2023
Oculis to Participate at Upcoming Investor Conferences
April 4, 2023
Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones
April 3, 2023
Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing
March 21, 2023
Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial
March 15, 2023
Decks
The 5 newest of 15 decks. Every deck is listed under its year.
- Investor Presentation (September 2026)
Investor deck · 43 slides · September 2026
- Investor Presentation (June 2026)
Investor deck · 28 slides · Jun 25, 2026
- Technical Presentation (May 2026)
Technical · 17 slides · May 29, 2026
- Shareholder Meeting (May 2026)
Shareholder meeting · 11 slides · May 13, 2026
- Corporate Update (October 2025)
Corporate update · 15 slides · Oct 6, 2025